1 | trials newsevents press releases | | | | | | | 2 | 0.49% |
2 | programs targeted protein inhibition | | | | | | | 2 | 0.49% |
3 | events in the news | | | | | | | 2 | 0.49% |
4 | in the news investors | | | | | | | 2 | 0.49% |
5 | the news financial reports | | | | | | | 2 | 0.49% |
6 | in the news financial | | | | | | | 2 | 0.49% |
7 | releases in the news | | | | | | | 2 | 0.49% |
8 | pipeline publications review clinical | | | | | | | 2 | 0.49% |
9 | the news investors overview | | | | | | | 2 | 0.49% |
10 | team board of directors | | | | | | | 2 | 0.49% |
11 | analyst coverage contact us | | | | | | | 2 | 0.49% |
12 | in the texas medical | | | | | | | 1 | 0.25% |
13 | foundation we are located | | | | | | | 1 | 0.25% |
14 | cancer foundation we are | | | | | | | 1 | 0.25% |
15 | pediatric cancer foundation we | | | | | | | 1 | 0.25% |
16 | skip to content salarius | | | | | | | 1 | 0.25% |
17 | national pediatric cancer foundation | | | | | | | 1 | 0.25% |
18 | the national pediatric cancer | | | | | | | 1 | 0.25% |
19 | the texas medical center | | | | | | | 1 | 0.25% |
20 | support from the national | | | | | | | 1 | 0.25% |
21 | received financial and inkind | | | | | | | 1 | 0.25% |
22 | also received financial and | | | | | | | 1 | 0.25% |
23 | has also received financial | | | | | | | 1 | 0.25% |
24 | salarius has also received | | | | | | | 1 | 0.25% |
25 | award salarius has also | | | | | | | 1 | 0.25% |
26 | development award salarius has | | | | | | | 1 | 0.25% |
27 | from the national pediatric | | | | | | | 1 | 0.25% |
28 | medical center innovation facility | | | | | | | 1 | 0.25% |
29 | texas medical center innovation | | | | | | | 1 | 0.25% |
30 | pharmaceuticals’ seclidemstat in patients | | | | | | | 1 | 0.25% |
31 | 2024 european hematology association | | | | | | | 1 | 0.25% |
32 | the 2024 european hematology | | | | | | | 1 | 0.25% |
33 | at the 2024 european | | | | | | | 1 | 0.25% |
34 | presented at the 2024 | | | | | | | 1 | 0.25% |
35 | with mds and cmml | | | | | | | 1 | 0.25% |
36 | patients with mds and | | | | | | | 1 | 0.25% |
37 | in patients with mds | | | | | | | 1 | 0.25% |
38 | seclidemstat in patients with | | | | | | | 1 | 0.25% |
39 | clinical data on salarius | | | | | | | 1 | 0.25% |
40 | texas cprit new company | | | | | | | 1 | 0.25% |